Holen Sie sich die Stockscreener-App
61.95
1.63%
-1.04
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences will present in New York and online - Stock Titan
MBX Biosciences, Inc. Announces Appointment of Jeff Held as Chief Legal Officer - marketscreener.com
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - The Manila Times
MBX Biosciences Share Price Chart (MBX) - Investing.com UK
MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? - simplywall.st
MBX Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Stability Report - vinanet.vn
MBX Biosciences (MBX), Why Is It Getting So Much Attention Now? - Sahm
MBX Biosciences doses first patient in phase 3 HP trial - Investing.com
MBX Biosciences doses first patient in phase 3 HP trial By Investing.com - Investing.com Nigeria
MBX BIOSCIENCES, INC. : JP MORGAN RESUMES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $88 - Bitget
JPMorgan Chase & Co. Initiates Coverage on MBX Biosciences (NASDAQ:MBX) - MarketBeat
Deep Track Capital Reduces MBX Biosciences Stake in Strategic Pr - GuruFocus
MBX (MBX) Move: Finishes 2.76% Lower at $66.51 on the Day; Technical View: the Supplied Trading Band Runs From $63.18 to $69.84 on the DayMean Reversion Trade - vinanet.vn
MBX (MBX) Snapshot: Finishes 0.13% Lower at $66.44 on the Day; Boundary Watch: $63.12 and $69.76 Define the Nearby Reference Levels for the Current SessionBollinger Squeeze - vinanet.vn
MBX Biosciences (NASDAQ: MBX) insider to sell 3,745 shares - Stock Titan
MBX Biosciences (MBX) Edges Lower to $68.12, Consolidating Between Support and ResistanceZigzag Correction - vinanet.vn
MBX Q2 2026 Earnings: Wider-than-Expected -$0.78 Loss Highlights Accelerated Pipeline InvestmentRevenue Estimate Trend - vinanet.vn
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX - MarketBeat
Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A - Stock Titan
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70 - Moomoo
MBX Biosciences (MBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Frazier funds detail 10.8% MBX Biosciences stake (MBX) in ownership update - Stock Titan
OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales - Stock Titan
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating - Moomoo
Truist Financial Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88 - Moomoo
MBX Biosciences, Inc. $MBX Stock Holdings Raised by The Manufacturers Life Insurance Company - MarketBeat
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121 - moomoo.com
MBX Biosciences (NASDAQ:MBX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88 - Moomoo
MBX Biosciences (MBX) Stock Analysis: Strong Buy Ratings and Significant Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. Stock 12‑Month Price Target Raised to $84.8, Implies 26% Upside - TradingView
MBX Biosciences Shares Lower After Q2 Loss Widens - marketscreener.com
MBX Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MBX Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences posts Q2 loss, advances obesity pipeline By Investing.com - Investing.com Australia
MBX Biosciences posts Q2 loss, advances obesity pipeline - Investing.com
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
MBX Biosciences posts $37.1 million Q2 net loss - Quiver Quantitative
Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, Vs. FactSet Est of $0.63 Loss - Moomoo
MBX Biosciences 2Q 2026: Net loss $(37.1M), EPS $(0.78) — 10-Q Summary - TradingView
MBX: Q2 net loss increased to $37.1M as R&D spending rose; cash reserves support operations into 2029 - tradingview.com
MBX Biosciences (Nasdaq: MBX) widens Q2 loss but holds $418.6M cash - Stock Titan
MBX: Advanced pipeline, strong cash position, and expanded obesity portfolio despite higher net loss - TradingView
MBX Biosciences Announces Q2 2026 Financial Results and MBX 4291 Clinical Trial Update - Kalkine Media
Insider Selling: MBX Biosciences (NASDAQ:MBX) Insider Sells $24,334.90 in Stock - MarketBeat
MBX Biosciences (MBX) CMO sells 370 shares to cover RSU taxes - Stock Titan
MBX: Advancing precision peptide therapies for endocrine and obesity indications with strong clinical momentum - TradingView
MBX Q2'26 Earnings: EPS estimate is (0.63) USD - TradingView
MBX Biosciences (NASDAQ:MBX) Reaches New 52-Week HighStill a Buy? - marketbeat.com
Mbx Biosciences stock hits all-time high of 69.5 USD By Investing.com - Investing.com India
MBX (MBX) affiliate plans to sell 936 vested common shares after prior sale - Stock Titan
Salomon Azoulay plans 370-share sale of MBX (NASDAQ: MBX) - Stock Titan
Mbx Biosciences stock hits all-time high of 69.5 USD - Investing.com
MBX Biosciences, Inc. (MBX) awards CFO 130,000 options and 28,000 RSUs - Stock Titan
MBX Biosciences, Inc. (MBX) grants CEO major option and RSU awards - Stock Titan
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):